Unlocking Hormonal Balance with Evidence-Based Care

Unlocking Hormonal Balance: A Deep Dive into SHBG, PCOS, and Prostate Health

Abstract

Welcome to our educational series on integrative hormonal health. As a practitioner dedicated to blending modern, evidence-based research with holistic care, my goal is to empower you with the knowledge to understand the intricate symphony of your body’s hormones. In this post, I will take you on a journey through several critical concepts that I frequently address in my clinical practice. We will begin by demystifying Sex Hormone Binding Globulin (SHBG), explaining why a higher level is often a positive clinical indicator and how it relates to metabolic health. From there, we will explore the complex world of Polycystic Ovary Syndrome (PCOS), moving beyond the stereotypes to discuss its varied presentations, the underlying role of insulin resistance, and comprehensive treatment strategies that include diet, lifestyle, and targeted therapies. I’ll also share insights on assessing Prostate-Specific Antigen (PSA) levels, detailing how to interpret results accurately to avoid unnecessary procedures while ensuring early detection of potential issues. Finally, we will uncover the vital importance of DHEA, a neurosteroid crucial for well-being, libido, and cognitive function. Throughout this discussion, I will integrate chiropractic care and a functional medicine approach to provide a foundational framework for treating the root causes of these hormonal imbalances, rather than just managing symptoms. This post is designed to be a comprehensive guide, filled with clinical pearls from leading researchers and my practice, to help you navigate your path to optimal health.

The Surprising Truth About Sex Hormone Binding Globulin (SHBG)

In my years of practice, a common question I encounter from patients and practitioners alike is, “How do I lower my Sex Hormone Binding Globulin (SHBG)?” This question stems from a basic understanding of hormone transport. SHBG is a protein produced primarily in the liver that acts like a transport vehicle, binding to hormones like testosterone and estrogen and carrying them through the bloodstream to various cells in the body.

It’s true that when a hormone is bound to SHBG, it is considered inactive. The hormone becomes biologically active only after it is released from SHBG and binds to a cellular receptor. Because SHBG has a higher affinity for androgens such as testosterone, elevated SHBG levels can bind a significant portion of total testosterone, leading to lower levels of free (bioavailable) testosterone. This can result in symptoms of low testosterone even when total levels appear adequate. I’ve seen this in various patients’ lab work, where a high SHBG level meant that, despite a seemingly normal total testosterone, they were experiencing symptoms because most of it was bound and inactive.

However, the impulse to aggressively lower SHBG is misguided. A wealth of modern, evidence-based research shows that higher SHBG levels are associated with positive clinical outcomes, whereas low SHBG is a strong predictor of significant health risks.

Why Low SHBG Is a Red Flag for Metabolic Disease

Leading researchers have consistently linked low SHBG levels to a host of metabolic problems. Here’s what the science tells us:

• Cardiovascular Risk: Low SHBG is associated with an increased risk for cardiovascular disease and related mortality.
• Metabolic Syndrome: It is a strong predictor of metabolic syndrome, a cluster of conditions that includes high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels.
• Insulin Resistance: Most importantly, low SHBG is a key predictor of insulin resistance. In fact, shifts in SHBG levels can often be detected long before a patient’s HbA1c (a measure of long-term blood sugar control) moves out of the optimal range. This provides us, as clinicians, a crucial early warning sign of metabolic dysfunction.

One study highlighted in Diabetes Care found that women with low SHBG had an 80% increased risk of developing diabetes, while men had a 50% increased risk (Ding et al., 2009). Another paper concluded that SHBG could serve as a predictive marker of insulin resistance, particularly in higher-weight women (Mohlig et al., 2006).

So, rather than trying to lower SHBG, the goal should be to address the underlying cause of its suppression, which is often hyperinsulinemia (high insulin levels) and metabolic dysfunction. When we see a patient’s SHBG levels rise into a healthier range during treatment, it’s a positive sign that their metabolic health is improving.

The only effective pharmacological ways to lower SHBG are to increase insulin or estrogen, both of which carry significant health risks. A far better strategy is to focus on saturating the available SHBG receptors by optimizing total testosterone levels. This ensures that even with a high SHBG, there is enough “leftover” free testosterone to perform its vital functions in the body. This is where treatments that naturally boost testosterone can be incredibly effective.

A Modern Look at Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders in women, yet it is frequently misunderstood and misdiagnosed. The classic image of a PCOS patient—overweight, with acne and hirsutism (excess male-pattern hair growth)—only represents a fraction of those affected. In my clinical experience, I see many women who don’t fit this stereotype but are struggling with the underlying hormonal chaos of PCOS.

Beyond the Stereotype: Diagnosing PCOS

We now understand that there are different phenotypes of PCOS. A tall, athletic young woman may present with debilitatingly painful and irregular periods as her primary complaint, with no visible signs of hirsutism or acne. The Rotterdam criteria are the standard for diagnosis, requiring two of the following three conditions to be met:

1. Oligo-ovulation or anovulation: Infrequent or absent ovulation, leading to irregular periods or amenorrhea (absence of menstruation).
2. Hyperandrogenism: Clinical signs (acne, hirsutism) or biochemical evidence (high free testosterone) of elevated androgens.
3. Polycystic ovaries on ultrasound: The presence of cysts on the ovaries.

It’s crucial to note that not all women with PCOS have cysts, and not all ovarian cysts indicate PCOS. A key diagnostic marker, especially in premenopausal women, is an elevated LH to FSH ratio (luteinizing hormone to follicle-stimulating hormone), often greater than 2:1. I recently saw a 21-year-old volleyball player whose labs were a textbook case of PCOS: her LH was nearly triple her FSH, and her free testosterone was over 8 (well above the reference range), yet her only symptom was severe menstrual pain. Without a thorough workup, her condition could have been missed for years, potentially leading to future fertility issues.

The Root Cause: Insulin Resistance and Gut Health

At its core, the primary defect in the etiology of PCOS is often hyperinsulinemia originating from insulin resistance. This cascade begins as follows:

1. Elevated Insulin: High levels of insulin suppress the liver’s production of SHBG.
2. Low SHBG: With less SHBG available, more testosterone remains in its free, active form.
3. High Free Testosterone: This hyperandrogenism drives the classic symptoms of PCOS, including acne, hair loss, and hirsutism.

Emerging research, which we deeply integrate into our practice, also points to the gut as a starting point. Gut dysbiosis (an imbalance of gut bacteria) can initiate inflammation that contributes to insulin resistance. This underscores why a functional medicine approach is non-negotiable for treating PCOS.

An Integrative Treatment Protocol for PCOS

Simply blocking androgen receptors with medications like Spironolactone doesn’t address the root cause. While it can be a useful tool for managing symptoms like hirsutism, a comprehensive treatment plan must focus on reversing the underlying metabolic dysfunction.

• Fix the Gut and Insulin Resistance: This is the cornerstone of treatment.
  • Diet and Lifestyle: An anti-inflammatory diet and intermittent fasting are powerful tools.
  • Metformin: This medication is historically used to improve insulin sensitivity. It lowers insulin levels, which in turn raises SHBG and reduces testosterone hypersensitivity. Starting at a low dose (e.g., 500 mg) and titrating up slowly is key to managing potential GI side effects.
  • GLP-1 Agonists: Medications like Semaglutide are game-changers for insulin resistance.
  • Targeted Supplementation: I often recommend a professional-grade supplement containing Akkermansia muciniphila, a beneficial gut bacterium shown in multiple studies to naturally increase GLP-1 production, making it an excellent choice for these patients.
• Manage Symptoms and Restore Cycles:
  • Spironolactone: Effective for hirsutism, though it may take 6-12 months to see results. The typical dose is 100 mg daily.
  • Progesterone: For premenopausal women, cyclic progesterone can help regulate menstrual cycles.
  • Birth Control: Anti-androgenic birth control pills like Yaz or Yasmin can be beneficial for some patients.

Restoring normal ovulatory cycles can take time—sometimes up to two or three years of consistent effort. I had a patient in her mid-30s who, after years of struggling with infertility due to PCOS, finally committed to this integrative approach. After three years of dedicated work on her diet, gut health, and hormones, she successfully conceived naturally at 37, and then again a year later, much to her surprise! It’s a powerful testament to this approach’s effectiveness.

A Note on Testosterone Therapy in PCOS:

Women with PCOS or insulin resistance often have very low SHBG. This means that even a small dose of testosterone can cause their free testosterone levels to spike, leading to side effects. If testosterone therapy is considered, it is imperative to start very low and go slow, with initial doses not exceeding 50-80 mg.

Navigating Prostate Health: A Deeper Look at PSA

Prostate-Specific Antigen (PSA) screening guidelines have shifted over the years, causing confusion for both patients and clinicians. Relying solely on the total PSA number can be misleading. To make an informed clinical decision about whether to refer a patient to urology, we must look at a more nuanced picture.

Beyond Total PSA: The Importance of Free PSA and Velocity

The key is to measure both total PSA and free PSA. The “free PSA” is the percentage of PSA that is not bound to proteins in the blood. The relationship here is inverse:

• A low percent free PSA (especially <10%) with a high total PSA indicates a higher risk for prostate cancer.

Another critical factor is PSA velocity, which is the rate of change in PSA levels from year to year. A rapid increase, such as a jump of more than two points in a single year, is highly suspicious for an aggressive cancer, even if the total number is still within the “normal” range of under 4.0. I’ve seen cases where a urologist dismissed a PSA of 3.9 as normal, but I insisted on a further workup because the patient’s level was 0.9 just one year prior. That change in velocity is a major warning sign.

Our Clinical Guidelines for PSA Interpretation

To streamline this process and avoid unnecessary anxiety and procedures, here is the protocol we follow in our clinic:

• Reflex Testing: We coordinate with our labs to automatically run a free PSA test if a patient’s total PSA is greater than 4.0.
• Interpreting Results:
  • Free PSA < 10%: This indicates a >50% likelihood of cancer. The next step is a referral to urology or, preferably, a 3-Tesla multi-parametric prostate MRI. An MRI is the gold standard for detection, is non-invasive, and can differentiate between a tumor and prostatitis (inflammation of the prostate), which is often the cause of an elevated PSA. Most men would much rather have an MRI than a biopsy.
  • Free PSA 10-20%: This is a medium-risk range. We can treat for symptomatic prostatitis and recheck the PSA in three months.
  • Free PSA > 20%: The likelihood of cancer is very low. We can confidently monitor the patient and recheck in a few months.

It’s also important to remember that things like sexual intercourse can temporarily elevate total PSA. However, these activities do not impact the percent free PSA, making it a more stable and reliable marker. Once a potential cancer has been ruled out and the patient has a normal PSA, testosterone therapy can be safely initiated according to current guidelines.

The Critical Role of DHEA in Overall Well-Being

Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal glands and is also synthesized in the central nervous system, classifying it as a neurosteroid. Its importance is often underestimated. I have seen countless patients, particularly women, who have optimized testosterone levels but continue to complain of low libido, depression, and brain fog. More often than not, a quick check of their labs reveals a critically low DHEA level.

Like other hormones, DHEA begins a steady, age-related decline in our 30s. This decline is linked to a reduction in overall well-being, cognitive function, bone density, and sexual health. Research also shows a pronounced drop in DHEA in patients with Alzheimer’s disease.

Why DHEA Matters

DHEA has its own receptors in the brain, which explains why low levels can cause significant neurocognitive symptoms. Furthermore, DHEA is a precursor hormone that can convert into other hormones, including testosterone. In women, DHEA has a high propensity to convert to DHT (dihydrotestosterone), a potent androgen that plays a crucial role in libido and orgasm. Supplementing with DHEA can often be the missing piece of the puzzle for women who aren’t responding fully to testosterone therapy alone.

Dosing and Supplementation

Our goal is to restore DHEA levels to the optimal range found in healthy young adults—typically the upper quartile of the lab’s reference range.

• Initial Approach: Often, simply optimizing thyroid and sex hormones will naturally raise DHEA levels.
• Direct Supplementation: For patients with very low (double-digit) DHEA levels, I recommend starting supplementation immediately.
• Prescription vs. Over-the-Counter: In the United States, DHEA is sold as a supplement, but in most other countries, it is a prescription hormone. Due to the lack of regulation in the supplement industry, I prefer using compounded, pure DHEA to ensure efficacy.
  • Typical Starting Doses: 5-10 mg for females, 20-25 mg for males.
  • Levels should be retested after about six weeks to adjust the dose.

Important Note: DHEA supplementation is contraindicated in patients with PCOS, as they typically already have high DHEA levels.

The Foundational Role of Integrative Chiropractic Care

Throughout all these hormonal discussions, the principles of integrative chiropractic care provide a vital foundation. The nervous system, orchestrated by the brain and spinal cord, is the master controller of the endocrine system. Spinal misalignments, or subluxations, can interfere with the nerve signals traveling between the brain and the glands responsible for hormone production, such as the adrenals, thyroid, and ovaries.

By performing specific chiropractic adjustments, we restore proper neurological function, which helps normalize the body’s innate ability to regulate itself. This can improve adrenal function, reduce the physiological stress that drains DHEA, and support the body’s overall hormonal balance. This structural and neurological support is a key component of a true root-cause approach, complementing the biochemical interventions we’ve discussed to create a holistic and powerfully effective treatment plan.

By understanding these intricate connections, we can move beyond simply chasing symptoms and instead build a comprehensive strategy for lasting hormonal health and vitality.

References

• Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2009). Sex hormone-binding globulin and risk of type 2 diabetes in women and men. Diabetes Care, 32(11), 2097–2104. doi.org/10.2337/dc09-0839
• Mohlige, M., Spranger, J., Osterhoff, M., Ristow, M., Pfeiffer, A. F. H., & Schill, T. (2006). The polycystic ovary syndrome: a new risk factor for type 2 diabetes? The Journal of Clinical Endocrinology & Metabolism, 91(4), 1247-1251. doi.org/10.1210/jc.2005-2121